TAVR IS SAFE AND IMPROVES CARDIAC FUNCTION IN PATIENTS WITH EXTREMELY LOW EJECTION FRACTIONS
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)34424-8
Abstract: Background: Patients with a very low ejection fraction (EF) have been excluded from major TAVR trials. As a consequence, the safety and efficacy of TAVR in this cohort remains uncertain. In this study, patients with… read more here.
Keywords: tavr safe; low ejection; ejection; cardiac function ... See more keywords
Hypothermia preconditioning improves cardiac contractility after cardiopulmonary resuscitation through AMPK-activated mitophagy
Sign Up to like & getrecommendations! Published in 2022 at "Experimental Biology and Medicine"
DOI: 10.1177/15353702221081546
Abstract: Hypothermia preconditioning (HPC) improves cardiac function after cardiac arrest, yet the mechanism is unclear. We hypothesized that HPC-activated adenosine monophosphate-activated protein kinase (AMPK) activity may be involved. Adult male Wistar rats were randomly divided into… read more here.
Keywords: compound; hypothermia preconditioning; group; improves cardiac ... See more keywords
The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24010446
Abstract: Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second direct myosin activator, has achieved encouraging results in preclinical and clinical studies, thus implicating its potential applicability in the treatment of heart failure… read more here.
Keywords: cardiac systolic; myosin activator; diastolic dysfunction; danicamtiv improves ... See more keywords